Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Connect Twitter with Market Wire News

BPMC News and Press, Blueprint Medicines Corporation


home / stock / bpmc / bpmc news

RSS
  • 3 Small-Caps That Might Be Acquisition Candidates

    A lot of small biotechs are fantastic buys right now. With Big Pharma sitting on a lot of cash, we might start seeing some smart acquisitions later this year. We asked a trio of contributors to pick the biotechs they're feeling most bullish about as potential buyout candidates in 2022. ...

    • May 09, 2022 04:00:00 pm
    • |
    • Motley Fool
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines Corporation (BPMC) CEO Kate Haviland On Q1 2022 Results - Earnings Call Transcript

    Blueprint Medicines Corporation (BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Offic...

    • May 03, 2022 01:10:28 pm
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines  GAAP EPS of -$1.79 beats by $0.10, revenue of $62.73M beats by $22.75M

    Blueprint Medicines  press release (NASDAQ:BPMC): Q1 GAAP EPS of -$1.79 beats by $0.10. Revenue of $62.73M (+190.7% Y/Y) beats by $22.75M. For further details see: Blueprint Medicines  GAAP EPS of -$1.79 beats by $0.10, revenue of $62.73M beats by $22.75M

    • May 03, 2022 07:16:26 am
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines Reports First Quarter 2022 Results

    Blueprint Medicines Reports First Quarter 2022 Results PR Newswire -- Achieved $23.8 million in AYVAKIT ® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway f...

    • May 03, 2022 07:00:00 am
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines  Q1 2022 Earnings Preview

    Blueprint Medicines  (NASDAQ:BPMC) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.85 (-7.6% Y/Y) and the consensus Revenue Estimate is $39.98M (+85.3% Y/Y). Over the last 1 year, BPMC has beaten EPS estimates 50% of...

    • May 02, 2022 12:12:57 pm
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

    Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 PR Newswire CAMBRIDGE, Mass. , April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conferenc...

    • April 26, 2022 08:00:00 am
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • 2 Under-the-Radar Biotech Stocks to Buy in 2022

    Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...

    • April 11, 2022 11:30:00 am
    • |
    • Motley Fool
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint, AstraZeneca ink deal to evaluate combination of lung cancer therapies in ongoing trials

    Blueprint Medicines (NASDAQ:BPMC) on Friday announced a clinical trial supply agreement with AstraZeneca (AZN) under which it will evaluate its investigational agents BLU-945 and BLU-701 in combination with osimertinib in its ongoing SYMPHONY and HARMONY trials, respectively. Blueprint also a...

    • April 08, 2022 01:57:55 pm
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer

    Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer PR Newswire -- Early dose escalation data show dose-dependent reductions in ctDNA and tumor bur...

    • April 08, 2022 01:00:00 pm
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • 7 Biotech Stocks to Buy With Key Catalysts for April

    InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blueprint Medicines (NASDAQ: BPMC ): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE: BMY ):  Food and Drug Admi...

    • April 05, 2022 06:59:46 am
    • |
    • InvestorPlace
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
Next 10
Stock Information

Blueprint Medicines Corporation Company Name:

BPMC Stock Symbol:

NASDAQ Market:

Blueprint Medicines Corporation Website:

BPMC News and Press, Blueprint Medicines Corporation

MENU
BPMC BPMC Quote BPMC Short BPMC News BPMC Articles BPMC Message Board
Get BPMC Alerts

News, Short Squeeze, Breakout and More Instantly...

Connect Twitter with Market Wire News
RECENT BPMC NEWS
  • BPMC - 3 Small-Caps That Might Be Acquisition Candidates

    A lot of small biotechs are fantastic buys right now. With Big Pharma sitting on a lot of cash, we might start seeing some smart acquisitions later this year. We asked a trio of contributors to pick the biotechs they're feeling most bullish about as potential buyout candidates in 2022. ...

  • BPMC - Blueprint Medicines Reports First Quarter 2022 Results

    Blueprint Medicines Reports First Quarter 2022 Results PR Newswire -- Achieved $23.8 million in AYVAKIT ® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway f...

  • BPMC - Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

    Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 PR Newswire CAMBRIDGE, Mass. , April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conferenc...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Join us on Discord

Join us on Discord

Follow us on discord to get immediate notifications!

Check out the New Market Wire News Discord Bot

Discord


Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email [email protected].

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected
Follow @MarketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News